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Chapter 5 Trial size
1. Introduction to trial size
One of the most important factors to consider in the design of an intervention trial (or indeed in the design of any
epidemiological study) is the choice of an appropriate trial size to answer the research question. Trials that are too small
may fail to detect important effects of an intervention on the outcomes of interest or may estimate those effects too
imprecisely. Trials that are larger than necessary are a waste of resources and may even lead to a loss in accuracy, as it
is often more difficult to maintain data quality and high coverage rates in a large trial than in a smaller one.
The choice of an appropriate trial size may be based on either the precision of outcome measures desired or the power
of the trial wanted. In Section 2, there is a discussion of the criteria used to make this choice. In Sections 3 and 4,
procedures are given for calculating trial size requirements in the simplest case where two groups of equal size are to be
compared. More complex designs are considered in Section 5. Special methods are necessary when the interventions
are allocated to groups (for example, communities, schools, or health facilities), rather than individuals, and these are
described in Section 6. Following this, in Section 7, two other factors that may influence the choice of trial size are
discussed—first, the need to allow for interim analyses of the results (see Section 7.1), and second, the effects of losses
to follow-up (see Section 7.2). In Section 8, the consequences of trials that are too small are discussed. Computer
programs can be used to carry out sample size calculations, and these are briefly discussed in Section 9.
The procedures described in this chapter should be regarded as providing only a rough estimate of the required trial
size, as they are often based on estimates of expected disease rates, subjective decisions about the size of effects that it
would be important to detect, and the use of approximate formulae. However, a rough estimate of the necessary size of
a trial is generally all that is needed for planning purposes. More comprehensive reviews of methods for the
determination of trial size requirements are available (Chow et al., 2008; Machin, 2009), but the methods given in this
chapter should be adequate for most purposes.
Readers who are not familiar with methods for the statistical analysis of trial data and, in particular, with the concepts
of confidence intervals (CIs) and significance tests may find it helpful to read Chapter 21, Section 2, before embarking
on this chapter, which is placed here because of the importance of considering trial size requirements at the design stage
of a trial.
A principal objective of most intervention trials is to estimate the effect of the intervention on the outcome or outcomes
of interest. Any such estimate is subject to error, and this error has two main components: bias and sampling error.
Possible sources of bias and ways of avoiding them are discussed in Chapters 4, 11, and 21. The second component
sampling error arises because the trial data come from only a sample of the population. This second component of error
is the focus of this chapter. Sampling error is reduced when the trial size is increased, whereas bias generally is not.
2. Criteria for determining trial size
2.1. Precision of effect measures
To select the appropriate sample size, it is necessary to decide how much sampling error in the estimate of the effect of
the intervention is acceptable and to select the sample size to achieve this precision. When the data are analysed, the
amount of sampling error is represented by the width of the confidence interval around the estimate of effect. The
narrower the CI, the greater the precision of the estimate, and the smaller the probable amount of sampling error. When
designing a trial, it is necessary therefore to decide the width of an acceptable CI around the chosen intervention effect.
Having made this decision, the method to select the required trial size is given in Section 3.
2.2. Power of the trial
An alternative approach is to choose a trial size which gives adequate power to detect an effect of a given magnitude.
The focus is then on the result of the significance test which will be conducted at the end of the trial. The significance
test assesses the evidence against the null hypothesis, which states that there is no true difference between the
interventions under comparison. A statistically significant result indicates that the data conflict with the null hypothesis
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and that there are grounds for rejecting the hypothesis that there is no difference in the effects of the interventions under
study on the outcomes of interest.
Because of the variations resulting from sampling error, it is never possible to be certain of obtaining a significant result
at the end of a trial, even if there is a real difference. It is necessary to consider the probability of obtaining a
statistically significant result in a trial, and this probability is called the power of the trial. Thus, a power of 80% to
detect a difference of a specified size means that, if the trial were to be conducted repeatedly, a statistically significant
result would be obtained four times out of five (80%) if the true difference was really of the specified size. The power
of a trial depends on the factors shown in Box 5.1.
The power also depends on whether a one-sided or two-sided significance test is to be performed (see Chapter 21,
Section 2.3) and on the underlying variability of the data. How the power may be calculated for given values of these
parameters is explained in Section 4.
When designing a trial, the objective is to ensure that the trial size is large enough to give high power if the true effect
of the intervention is large enough to be of public health importance.
2.3. Choice of criterion
The choice of which criterion (precision or power) should be used in any particular trial depends on the objectives of
the trial. If it is known unambiguously that the intervention has some effect (relative to the comparison (control) group),
it makes little sense to test the null hypothesis; rather the objective may be to estimate the magnitude of the effect and
to do this with some acceptable specified precision.
In trials of new interventions, it is often not known whether there will be any impact at all of the intervention on the
outcomes of interest, and what is required is ‘proof of concept’. In these circumstances, it may be sufficient to ensure
that there will be a good chance of obtaining a significant result if there is indeed an effect of some specified
magnitude. It should be emphasized, however, that, if this course is adopted, the estimates obtained may be very
imprecise. To illustrate this, suppose it is planned to compare two groups with respect to the mean of some variable,
and suppose the true difference between the group means is D. If the trial size is chosen to give 90% power (of
obtaining a significant difference with  on a two-sided test) if the difference is D, the 95% CI on D is expected
to extend roughly from 0.4 D to 1.6 D. This is a wide range and implies that the estimate of the effect of intervention
will be imprecise. In many situations, it may be more appropriate to choose the sample size by setting the width of the
CI, rather than to rely on power calculations.
2.4. Trials with multiple outcomes
The discussion in Sections 2.1 to 2.3 concerns factors influencing the choice of trial size, with respect to a particular
outcome measure. In most trials, several different outcomes are measured. For example, in a trial of the impact of
insecticide-treated mosquito-nets on childhood malaria, there may be interest in the effects of the intervention on
deaths, deaths attributable to malaria, episodes of clinical malaria, spleen sizes at the end of the malaria season, PCVs
at the end of the malaria season, and possibly other measures.
Chapter 12, Section 2 highlights the importance of defining in advance the primary outcome and a limited number of
secondary outcomes of a trial. In order to decide on the trial size, the investigator should first focus attention on the
primary outcome, as results for this outcome will be given the most weight when reporting the trial findings, and it is
essential that the trial is able to provide adequate results for this outcome. The methods of this chapter can then be used
to calculate the required trial size for the primary outcome and each of the secondary outcomes.
Ideally, the outcome that results in the largest trial size would be used to determine the size, as then, for other outcomes,
it would be known that better than the required precision or power would be achieved. It is often found, however, that
one or more of the outcomes would require a trial too large for the resources that are likely to be available. For
example, detecting changes in mortality, or cause-specific mortality, often requires very large trials. In these
circumstances, it may be decided to design the trial to be able to detect an impact on morbidity and accept that it is
unlikely to be able to generate conclusive findings about the effect on mortality. It is important to point out, however,
that, if a trial shows that an intervention has an impact on morbidity, it may be regarded as unethical to undertake a
further, larger trial to assess the impact on mortality. For this reason, it is generally advisable to ensure that trials are
conducted at an early stage in which the outcome of greatest public health importance is the endpoint around which the
trial is planned. This issue is discussed further in Chapter 6.
p<0.05
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Sometimes, different trial sizes may be used for different outcomes. For example, it might be possible to design a trial
in such a way that a large sample of participants are monitored for mortality, say by annual surveys, and only a
proportion of participants are monitored for morbidity, say by weekly visits.
If it is not feasible to design the trial to achieve adequate power or precision for the primary outcome, the trial should
either be abandoned or a different primary outcome should be adopted.
2.5. Practical constraints
In practice, statistical considerations are not the only factors that need to be taken into account in planning the size of an
investigation. Resources, in terms of staff, vehicles, laboratory capacity, time, or money, may limit the potential size of
a trial, and it is often necessary to compromise between the results of the trial size computations and what can be
managed with the available resources. Trying to do a trial that is beyond the capacity of the available resources is likely
to be unfruitful, as data quality is likely to suffer and the results may be subject to serious bias, or the trial may even
collapse completely, wasting the effort and money that have already been expended. If calculations indicate that a trial
of manageable size will yield power and/or precision that is unacceptably low, it is probably better not to conduct the
trial at all.
A useful approach to examine the trade-off between trial size (and thus cost) and power is to construct power curves for
one or two of the key outcome variables. Power curves show how power varies with trial size for different values of the
effect measure. Figure 5.1 shows power curves for malaria deaths in the mosquito-net trial discussed in Section 2.4,
assuming that equal numbers of children are to be allocated to the intervention and control groups and statistical
significance is to be based on a two-sided test at the 5% level. R represents the rate ratio of malaria deaths in the
intervention group, compared to the control group, so that  represents a reduction in the death rate of 70%. The
assumptions used to construct these curves are described in Section 4. The curves indicate that, if 1000 children were
followed for 1 year in each group (making 2000 children in all), there would be about a one in two chance of obtaining
a significant result (power = 50%), even if the reduction in the death rate was as high as 70%. A trial five times as large
as this would have a good chance (about 80%) of detecting a reduction in the death rate of 50% or more but would be
inadequate (about 40%) to detect a 30% reduction in the death rate.
3. Size to give adequate precision
This section describes how the trial size is determined if the aim is to obtain an estimate of the outcome of an
intervention with a specified level of precision. The simplest case to consider is where just two groups of about the
same size are to be compared (for example, the outcome of an intervention compared with that of a control group, or
the comparison of outcomes of two interventions). More complex designs are discussed in Section 5. The methodology
varies according to the type of outcome measure; the comparison of proportions, incidence rates, and means are
considered in Sections 3.1 to 3.3.
3.1. Comparison of proportions
In this section, outcomes are considered that are binary (yes or no) variables. This includes cumulative incidence or
risk, for example, the proportion of children experiencing at least one episode of clinical malaria during the follow-up
period. It also includes examination of the prevalence of some characteristic, for example, the presence of a palpable
spleen in a survey conducted at the end of the trial.
Suppose the true proportions in groups 1 and 2 are  and , respectively, giving a risk ratio (relative risk) of 
 The approximate 95% CI for R extends from  to Rf where, in this case, the factor f is given by:
where n is the number of children in each group, and f is commonly called the error factor.
The required value of f is chosen, and rough estimates are made of the values of  and R to enable the number required
in each group n to be calculated as:
R = 0.3
p1 p2
R = /p1 p2 R/f
f = exp {1.96√ [(1 − )/ (n ) + (1 − ) / (n )]}p1 p1 p2 p2
p2
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where  is the natural logarithm of f.
For example, in the mosquito-net trial, one of the outcomes of interest is the prevalence of splenomegaly (the
proportion of children with enlarged spleens) at the end of the trial. Prior data from the trial area suggest that, in the
control group, a prevalence of approximately 40% would be expected. Suppose the intervention is expected to roughly
halve the prevalence, so that  and an estimate of R is wanted to within about  This suggests setting f to
about 1.3 (because then the upper 95% confidence limit on R is  which is 0.15 above 
, and thus  so that around 300 children would need to be
studied in each group.
3.2. Comparison of incidence rates
Suppose a comparison of two groups is required, with respect to the rate of occurrence of some defined event over the
trial period. Suppose the true incidence rates are  and  in groups 1 and 2, respectively, where each rate represents
the number of events per person-year of observation. The rate ratio R (sometimes called incorrectly the relative risk,
instead of the relative rate) of the incidence rate in group 1, compared to the incidence rate in group 2, is given by 
 (see Chapter 21, Section 5 for methods of analysis for the comparison of rates). If the total follow-up time
for those in each group is y years (for example, y persons are each followed for 1 year, or  are each followed for 2
years), each group is said to experience y person-years of observation. The expected numbers of events in the two
groups will be  and  respectively. When the results are analysed, the approximate 95% CI for R is
expected to extend from  to Rf where:
To decide on the necessary size of the trial, make a rough estimate of the likely value of R, select the precision that is
required by specifying a value for f, the error factor, and calculate:
The trial size is then fixed so that the expected number of events in group 2 during the trial period is equal to the
calculated value  The expected number of events in group 1 will be 
It should be noted that these methods are only appropriate in the situation where each individual can experience only
one event during the trial period or where the number of individuals experiencing multiple events is very small. If most
individuals experience at least one event and many experience two or more, it is preferable to define a quantitative
outcome for each individual, representing the number of events experienced during the trial period, and to use the
methods described in Section 3.3.
Example: in the mosquito-net trial, suppose the trial groups are to consist of children aged 0–4 years and that the death
rate associated with malaria in the trial area for that age group is estimated to be roughly 10 per 1000 child-years. If
group 1 is the intervention group (treated bed-nets) and group 2 is the control group (no protection), R represents the
ratio of the intervention and control death rates. Suppose R is expected to be about 0.4, corresponding to a reduction in
the death rate of 60%. Suppose also that f is selected to be equal to 1.25, so that the 95% CI for R is expected to extend
from  to  In other words, it is desired to estimate the protective efficacy to within
about 10% of the true value (i.e. 50–70% around the estimated efficacy of 60%). Then:
n = + {[(R + 1) / (R )] − 2}(1.96/ f)loge
2 p2
floge
R = 0.5 ±0.15
Rf = 0.5 × 1.3 = 0.65
R(= 0.5 )) n = {[1.5/ (0.5 × 0.4)] − 2} = 307(1.96/ 1.3)loge
2
r1 r2
R = /r1 r2
y/2
= ye1 r1 = ye2 r2
R/f
f = exp {1.96√ [(1/ ) + (1/ )]} .e1 e2
= [(R + 1) /R] .e2 (1.96/ f)loge
2
e2 Re2
(0.4/1.25 = 0.32) (0.4 × 1.25 = 0.50)
= (1.4/0.4) = 270.e2 [1.96/ (1.25)]loge
2
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1.
To expect 270 deaths in the control group, it would be necessary to observe an estimated 27 000 child-years 
. This could be achieved by following 54 000 children for 6 months, or 27 000 children for 1 year,
or 13 500 for 2 years, and so on, assuming an expected death rate of ten per 1000 child-years in each of these scenarios.
The magnitude of the required trial size (27 000 child-years of observation in each group) illustrates that, when rare
events are being studied, very large samples are needed to obtain a precise estimate of the impact of an intervention.
3.3. Comparison of means
Quantitative outcomes may be analysed by comparing the means of the relevant variable in the intervention and control
groups. This could be the mean of the values recorded at a cross-sectional survey, for example, the mean weight of
children in the trial at the end of the trial. Alternatively, it could be the mean of the changes recorded between baseline
and follow-up surveys, for example, the mean change in weight (or weight velocity, i.e. the change in weight divided by
the time between the two measurements) among the children in the trial.
Suppose the true means in groups 1 and 2 are  and  These would generally be compared in terms of the difference
in the means,  The 95% CI for D is given by  where:
where  and  are the standard deviations of the outcome variable in the two groups.
An acceptable value of f is chosen; values of  and  are selected, and the required number in each group is
calculated as:
An estimate of the standard deviation of the outcome variable is often available from other studies. It is usually
reasonable to assume that the standard deviation will be roughly similar in the two trial groups. If no other estimate is
available, a rough approximation can be obtained by taking one-quarter of the likely range of the variable.
Example: In the mosquito-net trial, another outcome of interest is the PCV, or haematocrit, measured in blood samples
taken from the children at the end of the trial. From previous data, the mean PCV in the control group is expected to be
about 33.0, with a standard deviation of about 5.0 (the normal range is about , and it has been assumed that the
normal range covers four standard deviations (i.e. ). An increase in mean PCV in the intervention group of between
2.0 and 3.0 is expected, and it is required to estimate the difference D between the two groups to within about 0.5, so
that . Assuming that the standard deviation is about 5.0 in both groups:
4. Size to give adequate power
The alternative approach to setting trial size is based upon selecting the trial size to achieve a specified power. In order
to do this, the following must be specified:
What size of difference, D, between the two groups would be of clinical or public health importance? The trial size
will be chosen so it would have a good chance of detecting this size of true difference, i.e. there would be a good
chance of obtaining a statistically significant result, thus concluding that there is a real difference between the two
trial arms. D is the true difference between the two groups, not the estimated difference as measured in the trial.
Very small differences are generally of no public health importance, and it would not be of concern if they were not
detected in the trial. The general principle, in most cases, is to choose D to be the minimum difference which would
be of public health relevance and therefore be important to detect in a trial. Note that ‘detecting’ D means that a
significant difference is obtained, indicating that there is some difference between the two groups. This does not
[= 270/ (10/1000)]
μ1 μ2.
D= −μ1 μ2. D ± f,











n = ( + ) = 768.(1.96/0.5)2 5.02 5.02





mean that the difference is estimated precisely. To ensure a precise estimate is obtained, the approach of Section 3
should be used.
Having specified D, the investigators must decide how confident they wish to be of obtaining a significant result if
this were the true difference between the groups. In other words, the power is set for this value of D. Note that, if
the true difference between the groups is actually larger than D, the power of the trial will be larger than the value
set. The required power is specified in the calculations by choosing the corresponding value of  as shown in
Table 5.1. Commonly chosen values for the power are 80%, 90%, and 95%, the corresponding values of  being
0.84, 1.28, and 1.64. It would generally be regarded as unsatisfactory to proceed with a trial with a power of less
than 70% for the primary outcome, because that means that one would have a more than 30% chance of ‘missing’ a
true difference of D.
The significance level must also be specified for the comparison of the two groups under study. This is entered into
the calculations in terms of the parameter  The commonest choice for the required p-value is 0.05, corresponding
to a  of 1.96. Alternative values might be 0.01 or 0.001, corresponding to  values of 2.58 or 3.29, respectively. It
is assumed throughout this chapter that two-sided significance tests are to be used (see Chapter 21, Section 2.3). A
significance level of 0.05 is assumed in the numerical examples, unless otherwise stated.
In addition, certain additional information must be specified, which varies according to the type of measure being
examined. This may be a rough estimate of the rates or proportions that are expected, or an estimate of the standard
deviation for a quantitative variable. Note that, if these quantities were known exactly, no trial would be needed!
Only rough estimates are required.
Having specified these values, the formulae or tables given in Sections 4.1 to 4.3 can be used to calculate the required
trial size.
It is often useful, however, to proceed in the opposite direction, i.e. to explore the power that would be achieved for a
range of possible trial sizes and for a range of possible values of the true difference D. This enables the construction of
power curves, as illustrated in Figure 5.1. Formulae for this approach are also given in Sections 4.1 to 4.3.
4.1. Comparison of proportions
The trial size required in each group to detect a specified difference , with power specified by  and
significance level specified by  is given by:
where p is the average of  and .
For 90% power and significance at  this simplifies to:
Table 5.2 shows the required trial size for a range of values of  and  for 80%, 90%, or 95% power.
To calculate the power of a trial of specified size, calculate as follows, and refer the value of  to Table 5.1.
Example: assume that the spleen rate in the control group of the mosquito-net trial is around 40%. To have very high
power (say 95%) of detecting a significant effect if the intervention reduces the spleen rate to 30% (so that  the





D = −p1 p2 z2
z1,
n = [ 2p (1 − p)] /( + )z1 z2 2 ( − )p1 p2 2
p1 p2
p<0.05,




= (√ {n/ [2p (1 − p)]}) (| − |) − .z2 p1 p2 z1
p=0.35
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If the true risk ratio is R and we wish to power the trial, such that the lower confidence limit on the risk ratio will be
greater than or equal to  where  is the lowest acceptable efficacy (say, for whether or not to implement the
intervention in a public health system, i.e. we need to be sure that the efficacy is at least ), the required sample size
is:
4.2. Comparison of incidence rates
For a specified difference  and values of  and  representing the required significance level and power,
the required number of person-years in each group is given by:
where  and  are the expected rates per person-year in the two groups.
A rough estimate of the average of the two rates is therefore required, i.e.  For 90% power and
significance at , this formula simplifies to:
An alternative, but equivalent, formula gives the number of events required in group 2, the control group, in terms of
the rate ratio R, for which the specified power is required:
This formula was used to construct Table 5.3, which shows the number of events needed in group 2 to detect a rate ratio
of R with 80%, 90%, or 95% power. The total number of events needed in both groups can be calculated as 
Since this can be computed without specifying the assumed rates in the two trial groups, this provides a particularly
helpful approach when the rates are uncertain. Thus, in an endpoint-driven trial, we can specify the number of events
that need to be observed to reach the required power, after which recruitment or follow-up may be terminated.
To calculate the power for a given trial size, compute:
where  is the absolute value of the difference between the two rates.
Refer the resulting value of  to Table 5.1 to determine the power of the trial.
Example: Assume, in the mosquito-net trial, that the death rate from malaria in the control group is 10/1000 child-
years, so that  Eighty per cent power is wanted to detect a significant effect if the true rate in children with
bed-nets is reduced by 70% to  The number of child-years of observation required in each group is given
by:
n = [ (2 × 0.35 × 0.65)] / = 590.(1.96 + 1.64)2 (0.3 − 0.4)2
RL RL
RL
n = [(1 − )/( ) + (1 − )/( )]/ .( + )z1 z2
2
p1 p1 p2 p1 [ (R/ )]loge RL
2
D = −r1 r2 z1 z2
y = [ ( + )] /( + )z1 z2 2 r1 r2 ( − )r1 r2 2
r1 r2
[( + ) /2]r1 r2
p<0.05
y = [10.5 ( + )] / .r1 r2 ( − )r1 r2
2
= [ (1 + R)] / .e2 ( + )z1 z2 2 (1 − R)2
(1 + R ).e2
= {√ [n/ ( + )]} (| − |) −z2 r1 r2 r1 r2 z1
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The power curves shown in Figure 5.1 were constructed using the same assumption concerning the death rate in
controls. For example, with y = 2000  and a rate ratio of  (corresponding to a death rate of 7 per 1000
child-years in the intervention group), giving a power of 18% (Table 5.1):
These formulae are used to ensure that there is a high probability of rejecting the null hypothesis if the true effect is of
the assumed size. However, this may still mean that the lower confidence limit for the effect size is close to the null,
and this may provide insufficient evidence to recommend widespread adoption of the intervention. A larger sample size
will be needed to ensure that the lower confidence limit exceeds a given value.
Suppose the assumed value of the rate ratio is R and that we wish to power the trial so that there is a high probability
that the CI excludes a value  corresponding to the lower limit of efficacy desired. Then the required sample size is
given by the formula:
Example: In the mosquito-net trial, we found that 2080 child-years were required in each trial group to reject the null
hypothesis with 80% power if the true rate ratio R was 0.3, corresponding to an efficacy of 70%. Now suppose we wish
to ensure that there is an 80% chance that the lower 95% CI for the efficacy exceeds 30%, corresponding to 
Applying the formula, we obtain the following, demonstrating the substantial increase in sample size that this would
necessitate:
4.3. Comparison of means
The trial size required in each group to detect a specified difference  with power specified by  and the
significance level specified by  is given by:
where  and  are the standard deviations of the outcome variable in groups 1 and 2, respectively.
For 90% power and significance at  this simplifies to:
To calculate the power of a trial of specified size, calculate the following, and refer the value of  to Table 5.1:
y = [ (0.003 + 0.010)] / = 2080.(1.96 + 0.84)2 (−0.007)2
y=2000 R = 0.7
= {√ [2000/ (0.007 + 0.010)]} (|0.007 − 0.010|) − 1.96 = −0.93.z2
RL
y = (1/ + 1/ ) / .( + )z1 z2
2
r1 r2 [ (R/ )]loge RL
2
= 0.7.RL
y = (1/0.010 + 1/0.003) / = 4732.(1.96 + 0.84)2 [ (0.3/0.7)]loge
2
D = −μ1 μ2, z2
z1,




n = 10.5 ( + ) / .σ21 σ
2
2 ( − )μ1 μ2
2
z2
= {√[n/ ( + )]} (| − |) − .z2 σ21 σ
2
2 μ1 μ2 z1
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Estimates of  and  may be obtained from previous studies or from a pilot study. If appropriate values cannot be
determined, an alternative is to dichotomize the continuous outcome variable and use the sample size formulae for
comparison of proportions given in Section 4.1. This will give a conservative estimate of sample size, as it ignores
some of the information, but will ensure an adequate sample size in the face of uncertainty regarding the standard
deviations.
Example: In the mosquito-net trial, the mean PCV in the control group at the end of the trial is expected to be 33.0,
with a standard deviation of 5.0. To have 90% power of detecting a significant effect if the intervention increases the
mean PCV by 1.5, the number of children required in each group is given by:
Suppose it turns out that only 150 children are available for study in each group. The power in these circumstances is
given by the following, corresponding to a power of about 74%:
A summary of the various formulae that have been given for calculating the trial size requirements for the comparison
of two groups of equal size is given in Table 5.4.
5. More complex designs
5.1. Two groups of unequal size
Sections 3 and 4 considered the simplest situation where the two groups to be compared are of equal size. Sometimes,
there may be reasons for wishing to allocate more individuals to one group than to the other. For example, if an
experimental drug is very expensive, it may be desired to minimize the number of patients allocated to the drug, and so
the trial may be arranged so that there are two or three patients given the old drug for every patient given the new drug.
In order to maintain the same power as in the equal allocation scheme, a larger total trial size will be needed, but the
number given the new drug will be smaller. Conversely, in a trial of a new vaccine, it may be decided to allocate twice
as many participants to the vaccinated group as are included in the placebo group, in order to increase the size of the
safety database for the new vaccine, before it goes into public health programmes.
Let the size of the smaller of the two groups be  and suppose the ratio of the two sample sizes to be k, so that there
will be  individuals in the other group  Then, to achieve approximately the same power and precision as in a
trial with an equal number n in each group,  should be chosen as:
Examples are shown in Table 5.5 for various values of k. Notice that the number allocated to the smaller group can
never be reduced below half the number required with equal groups. Little is gained by increasing k beyond 3 or 4,
since, beyond this point, even a substantial increase in  achieves only a small reduction in 
5.2. Comparison of more than two groups
Field trials comparing two groups (for example, intervention and control, or treatment A and treatment B) are by far the
commonest. However, in some trials, three or more groups may be compared. For example, in a trial of a new vaccine,
there may be four trial groups receiving different doses of the vaccine. It is unusual for field trials to have more than
four groups, because of logistical constraints or trial size limitations.
It is suggested that, in designing a trial with three or more groups, the investigator should decide which pair-wise
comparisons between groups are of central interest. The methods of Sections 3 and 4 can then be used to decide on the
σ1 σ2
n = [ ( + )] / = 233.(1.96 + 1.28)2 5.02 5.02 (1.5)2
= {√[150/ ( + )]} (|1.5|) − 1.96 = 0.64.z2 5.02 5.02
n1
kn1 (k > 1)
n1
= n (k + 1) / (2k) .n1
n2 n1.
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trial size required in each group. Where there is one control group for comparison with several intervention groups, it is
likely that the main pair-wise comparisons will be between each intervention group and the control group. Note,
however, that direct comparisons between the intervention groups may then be inadequately powered, since, if each of
the interventions has some effect, differences between the intervention groups may be smaller than when each is
compared with the control group.
5.3. Factorial designs
As discussed in Chapter 4, Section 3.2, some trials are designed to look simultaneously at the effects of two
interventions, using a factorial design. In a  factorial trial of two interventions A and B, for example, participants
are randomly allocated between four trial groups receiving A only, B only, both A and B, or a control group receiving
neither intervention. If the effects of A and B can be assumed independent, so that the effect of A is the same in the
presence or absence of B and vice versa, then this trial design allows us to measure the effects of the two interventions
for roughly the price of a single two-group trial measuring the effect of one intervention.
Under these conditions of independence, the main change to the calculation of sample size for a  factorial trial is
that the expected outcome in the intervention and control groups for intervention A has to be adjusted for the expected
effect of intervention B. This is explained with an example.
For example, suppose we are interested in the effects of iron supplements (intervention A) and anti-malarial
prophylaxis (intervention B) on anaemia during pregnancy. Suppose that the prevalence of anaemia in the control group
that receives neither A nor B is expected to be 30%, that each intervention is expected to reduce the prevalence
proportionally by 20%, and that these effects are independent. Then the expected prevalences in the four arms of the
trial will be: control—30%; A only—24%; B only—24%; —19.2%. In this factorial trial, the effect of
intervention A will be estimated by comparing the prevalence between groups  and B only, and between group A
only and the control group. The overall prevalence in the two groups given intervention A will be 
 and in the two groups not given A  Since the difference in prevalences is
slightly smaller than in a simple two-group trial, the total sample size will be somewhat larger for the factorial design.
In some factorial trials, we may wish to look explicitly at whether the effects of the two interventions are independent.
This requires a test for interaction or effect modification, since we are interested in whether the effect of A, for
example, differs according to the presence or absence of B. Testing for interaction generally requires a much larger
sample size than a simple comparison of two groups. As a rough guideline, the total sample size for a  factorial
trial would need to be multiplied by at least four to detect a substantial interaction (of similar size to the main effects of
the interventions) between the effects of two interventions.
5.4. Equivalence and non-inferiority trials
In most field trials, the objective is to determine whether a new intervention is superior to a control intervention, for
example, an existing intervention. In some cases, however, we may wish to demonstrate that a new intervention is
equivalent, or at least not inferior, to an existing intervention. For example, suppose the current treatment for some
condition is known to be highly effective, but it is also expensive and has some unpleasant side effects. Now suppose
that a new treatment has been developed which is less costly and has fewer side effects. This would probably be
considered for implementation, as long as it is as effective as the old treatment. In this case, we may decide to conduct
an equivalence trial aimed at determining whether the two treatments have similar efficacy.
For a full discussion of such trials, the reader is referred to Blackwelder (1982) or Wang and Bakhai (2006). However, a
simple example is given to illustrate the required sample size calculations.
Example: Suppose that the current treatment for TB has a cure rate of around 90% but requires a prolonged course of
treatment. A new shorter-course regimen has been developed which would have advantages, in terms of cost,
convenience, and adherence. We wish to carry out a trial to determine whether the cure rate for the short-course
regimen is equivalent to that of the current regimen. We would usually do this by defining a lower limit for the cure
rate, below which we would no longer consider the treatments to be ‘equivalent’. If we set this at 85%, the trial would
need to be powered to demonstrate that the difference in cure rates is no more than 5%. The null hypothesis is now that
the new treatment is inferior to the old treatment, and we power the trial to reject this null hypothesis and declare
equivalence of the two treatments if the new treatment has a cure rate that is not inferior to the standard treatment by
more than the specified 5%.





21.6% [= (24 + 19.2) /2] 27% [= (30 + 24) /2]
2 × 2
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In this equation, p is the expected cure rate of 90% in both groups, assuming equivalence, and D is the acceptable
margin of inferiority, which is 5% in this example. Thus, for 90% power and a two-sided significance test with
we have:
In general, large sample sizes are needed to test equivalence.
6. Interventions allocated to groups
The methods described in Sections 3 to 5 all assume that individuals are to be the units of allocation. In other words,
the trial groups will be constructed effectively by making a complete list of the individuals available for the trial and
randomly selecting which individuals are to be allocated to each trial group. As explained in Chapter 4, Section 4,
however, many field trials are not organized in this way. Instead, groups of individuals are allocated to the interventions
under study. These groups are often called clusters and may correspond to communities, for example, villages, hamlets,
or defined sectors of an urban area; institutions such as schools or workplaces; or patients attending a particular health
facility.
Trials in which communities or other types of cluster are randomly allocated to the different arms of the trial are known
as cluster randomized trials, and sample size calculations for such trials are presented in Section 6.1. Stepped wedge
trials are a modified form of cluster randomized trial and are discussed in Section 6.2.
6.1. Cluster randomized trials
If clusters are randomly allocated to the different trial arms, the cluster should also be used as the unit of analysis, even
though assessments of outcome are made on individuals within clusters (see Chapter 21, Section 8). For example,
suppose the mosquito-net trial is to be conducted as follows. A number of villages (say 20) are to be randomly divided
into two equal-sized groups. In the ten villages in the first group, the entire population of each village will be given
mosquito-nets, while the second group of ten villages will serve as controls. The analysis of the impact of mosquito-
nets on the incidence of clinical malaria would be made by calculating the (age-adjusted) incidence rate in each village
and comparing the ten rates for the intervention villages with the ten rates for the control villages. This would be
achieved by treating the (age-adjusted) rate as the quantitative outcome measured for each village and comparing these,
using the unpaired t-test or the non-parametric rank sum test (see Chapter 21, Section 8). If analysing proportions,
rather than incidence rates, the principle is the same—the (age-adjusted) proportion would be treated as the quantitative
outcome for each cluster.
When allocation is by cluster, the trial size formulae have to be adjusted to allow for intrinsic variation between
communities. Suppose first that incidence rates in the two groups are to be compared. The required number of clusters c
is given by:
In this formula, y is the person-years of observation in each cluster, while  and  are the average rates in the
intervention and control clusters, respectively. The intrinsic variation between clusters is measured by k, the coefficient
of variation of the (true) incidence rates among the clusters in each group, and is defined as the standard deviation of
the rates divided by the average rate. The value of k is assumed similar in the intervention and control groups, so that
the relative variability remains the same following intervention.
If proportions are to be compared, the required number of clusters is given by:
n = [ 2p (1 − p)] / .( + )z1 z2 2 D2
p=0.05,
n = [ × 2 × 0.90 × 0.10] / = 756.(1.96 + 1.28)2 0.052





2 ( − )r1 r2
2
r1 r2
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In this formula, n is the trial size in each community;  and  are the average proportions in the intervention and
control groups, respectively; p is the average of  and  and k is the coefficient of variation of the (true) proportions
among the clusters in each group.
An estimate of k will sometimes be available from previous data on the same clusters or from a pilot study. If no data
are available, it may be necessary to make an arbitrary, but plausible, assumption about the value of k. For example, 
 implies that the true rates in each group vary roughly between , i.e. between 0.5r and 1.5r. In
general, k is unlikely to exceed 0.5.
Example: Suppose the mosquito-net trial is to be conducted by allocating the intervention at the village level. The
incidence rate of clinical malaria among children before intervention is 10 per 1000 child-weeks of observation, and the
trial is to be designed to give 90% power if the intervention reduces the incidence rate by 50%. There are about 50
eligible children per village, and it is intended to continue follow-up for 1 year, so that y is approximately 2500 child-
weeks. No information is available on between-village variation in incidence rates. Taking , the number of
villages required per group is given by the following, so that roughly seven villages would be needed in each group:
Note that this would give a total of 17 500 child-weeks of observation in each group, compared with 6300 child-weeks
if individual children were randomized to receive mosquito-nets. Figure 5.2 shows the number of villages required in
each group, depending on the child-weeks of observation per village and the value of k.
The effect of group allocation on the total trial size needed will depend on the degree to which individuals within a
cluster are more likely to be similar to each other than individuals in a different cluster for the outcome measure in the
trial. If there is no heterogeneity between clusters in the outcome of interest, in the sense that the variation between the
cluster-specific rates or means is no more than would be expected to occur by chance, due to sampling variations, the
total trial size will be approximately the same as if the interventions were allocated to individuals. For most outcomes,
however, there will be real differences between clusters, and, in these circumstances, the required trial size will be
greater than with individual allocation. The ratio of the required trial sizes with cluster and individual allocation is
sometimes called the design effect. Unfortunately, no single value for the design effect can be assumed, as its value
depends on the variability of the outcome of interest between clusters and on the sizes of the clusters, and so it is
recommended that the required sample size is estimated explicitly.
Note that, even if the calculations suggest that less than four clusters are required in each group, it is preferable to have
at least four in each group. With so few units of observation, the use of non-parametric procedures, such as the rank
sum test, is generally preferred for the analysis, and a sample size of at least four in each group is needed to have any
chance of obtaining a significant result when this test is used.
It may be possible to reduce the required number of communities by adopting a matched design. For example, this can
be done by using the baseline study to arrange the clusters into pairs, in which the rates of the outcome of interest are
similar, and randomly selecting one member of each pair to receive the intervention. However, it is difficult to quantify
the effect of this approach on the number of clusters required. To do this, information is required on the variability of
the treatment effect between communities and on the extent to which the baseline data are predictive of the rates that
would be observed during the follow-up period in the absence of intervention, and this information is rarely available.
With a paired design, at least six clusters are required in each group in order to be able to obtain a significant difference
using a non-parametric statistical test.
Further information on sample size calculations for cluster randomized trials is given in Hayes and Bennett (1999) and
Hayes and Moulton (2009).
According to the number of child-weeks of observation in each community and the extent of variation in rates of
clinical malaria between communities (k is the coefficient of variation of the incidence rates; see text). The average
incidence rate of clinical malaria in the absence of the intervention is assumed to be ten per 10 000 weeks of








k = 0.25 ± 2kr1 r1
k = 0.25
c = 1 + [(0.01 + 0.005) /2500 + ( + )] / = 6.8.(1.96 + 1.28)2 0.252 0.012 0.0052 (0.01 − 0.005)2
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observation, and the trial is required to have 90% power to detect a 50% reduction in the incidence of malaria at the p <
0.05 level of statistical significance.
6.2. Stepped wedge trials
The stepped wedge design was introduced in Chapter 4, Section 4.3 and is a modification of the cluster randomized
trial, in which all clusters commence the trial in the control group. The intervention is then introduced gradually into
the clusters in random order, until, at the end of the trial, all the clusters are in the intervention group.
A consequence of the stepped wedge design is that, at most time points during the trial, there will be unequal numbers
of clusters in the intervention and control groups. This means that, when secular trends are accounted for by comparing
intervention to control groups at each step, a stepped wedge trial can have lower power and precision than a standard
cluster randomized trial of the same size, in which the numbers of intervention and control clusters are equal
throughout. When there is zero intra-cluster correlation, the trial will need up to 50% more clusters. To adjust for this,
the number of clusters has to be multiplied by a correction factor which depends on the number of ‘steps’ in the stepped
wedge design. If there are five steps, the correction factor is 1.3, rising to approximately 1.4 for numbers of steps
between 10 and 20. When intra-cluster correlation is large enough, the gain in efficiency that can be made by taking
advantage of the pre–post information on each cluster can overtake this factor, making a stepped wedge trial more
efficient than a parallel trial. To be conservative, however, it may be best to inflate the number of clusters.
Example: In the mosquito-net trial discussed earlier, the sample size calculation showed that we needed seven clusters
in each arm or a total of 14 clusters. If we now propose to carry out this trial using a stepped wedge trial, a conservative
correction would be to multiply this number by 1.4, giving 20 clusters. For example, this might be implemented with
ten steps over a 5-year period, providing nets to two randomly chosen clusters each half year.
7. Other factors influencing choice of trial size
7.1. Allowance for interim analyses
It is sometimes desirable to incorporate interim analyses into the trial plan, involving review of the results at (say) 6-
monthly or annual intervals. If an interim analysis indicates that there is already strong evidence of the superiority of
one of the interventions under study, the trial can be terminated in order that participants are no longer subjected to an
intervention which is known to be inferior. The incorporation of interim analyses may be particularly valuable if the
trial is planned to continue for several years, with the gradual accumulation of cases of the outcome of interest, or if
individuals or communities are entered into the trial sequentially.
There are also disadvantages in carrying out interim analyses, however. If the trial is terminated early, because the
intervention appears to be beneficial, there may be no opportunity of detecting any long-term effects of the
intervention, including how efficacy changes with time or long-term adverse consequences of the intervention. Also,
although a significant effect of the intervention may be demonstrated, the precision of the estimate of effect may be too
low to be of much value.
If, after careful consideration, it is decided that interim analyses are to be conducted, these need to be planned in the
trial design. It is necessary to employ a more stringent significance level for each analysis (interim and final) to
maintain the same overall level of significance.
Details of the implications of interim analyses are given by Geller and Pocock (1987). As a rough guide, the following
approach is suggested. It is rarely advantageous to plan for more than three or four interim analyses. It is recommended
therefore that, for trials planned to continue for 2–4 years, the trial plan should include no more than two interim
analyses (plus the final analysis). To compensate for this, the maximum trial size (i.e. the maximum person-years of
observation if the trial proceeds to completion) should be increased by about 15%. A stringent significance level of 
 should be used at each interim analysis to decide whether or not the trial should be terminated. This means that,
if the trial proceeds to completion, an unadjusted  would correspond to an adjusted  if the interim
analyses are taken into account, i.e little power has been lost in performing the interim analyses.
7.2. Allowance for losses
Losses to follow-up occur in most longitudinal studies. Individuals may be lost, because they move away from the trial
area, they die from some cause unrelated to the outcome of interest, they refuse to continue with the trial, they are away
from home at the time of a follow-up survey, or for some other reason.
p=0.01
p<0.04 p<0.05
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Losses like these are of concern for two reasons. First, they are a possible source of bias, as the individuals who are lost
often differ in important respects from those who remain in the trial. Second, they reduce the size of the sample
available for analysis, and this decreases the power or precision of the trial.
For these reasons, it is important to make every attempt to reduce the number of losses to a minimum. However, it is
rarely possible to avoid losses completely. The extent of the problem will vary, according to circumstances, but, as a
rough guide, in a longitudinal trial of a rural community with 2 years of follow-up, losses of around 20% would not be
unusual.
The reduced power or precision resulting from losses may be avoided by increasing the initial sample size, in order to
compensate for the expected number of losses. For example, if sample size calculations suggest that 240 subjects are
required and a 20% loss rate is expected, the sample size should be increased to 300 (because 80% of 300 gives 240). It
is important to stress that sample size inflation only deals with the problem due to the reduction in the size of the
sample available for analysis; it does not solve any potential problems due to bias. So, even if the sample size has been
inflated to allow for losses to follow-up, it is still necessary to strive to minimize losses, in order to avoid bias.
8. The consequences of trials that are too small
The methods outlined in this chapter for selecting an adequate sample size have been available for many years, but it is
probably not an exaggeration to state that the majority of intervention trials are much too small. Although there is an
increasing awareness of the need to enrol a large enough sample, this chapter is concluded by discussing the
consequences of choosing a sample size that is too small.
First, suppose that the intervention under study has little or no effect on the outcome of interest. The difference
observed in a trial is likely therefore to be non-significant. However, the width of the CI for the effect measure (for
example, the relative risk) will depend on the sample size. If the sample is small, the CI will be very wide, and so, even
though it will probably include the null value (a zero difference between the groups, or a relative risk of 1), it will
extend to include large values of the effect measure. In other words, the trial will have failed to establish that the
intervention is unlikely to have an effect of public health or clinical importance. For example, in the mosquito-net trial,
suppose only 50 children were included in each group, and suppose the observed spleen rates in the two groups were
identical at 40%, giving an estimated relative risk of  The approximate 95% CI for R would extend from 0.62 to
1.62 (see Section 3.1). A relative risk of 0.62 would imply a very substantial effect, i.e. a reduction in spleen rate from
40% to 25%, and this small trial would be unable to exclude such an effect as being very unlikely. If the sample size in
each group were increased to 500, the 95% CI would extend only from 0.86 to 1.16, a much narrower interval.
Suppose that the intervention does have an appreciable effect. A trial that is too small will have low power, i.e. it will
have little chance of giving a statistically significant difference. In other words, there is little chance to demonstrate that
the intervention has an effect. In the example, if the true effect of the intervention is to reduce the spleen rate from 40%
to 25%, a sample size of 50 in each group would give a power of only 36%. A total of 205 children would be needed in
each group to give 90% power (Table 5.2). Even if a significant difference is found, the CI on the effect will still be
very wide, so there will be uncertainty at the end of the trial whether the effect of the intervention is small and
unimportant, or very large and of major importance.
The conduct of trials that are too small has consequences extending beyond the results of the specific trial. There is
considerable evidence that trials showing large effects are more likely to be published than those showing little or no
effect. Suppose a number of small trials of a specific intervention are conducted. Because of the large sampling error
implied by small sample sizes, a few of these trials will produce estimates of the effect of the intervention that are much
larger than the true effect. These trials are more likely to be published, and the result is that the findings in the literature
are likely to overestimate considerably the true effects of interventions. This publication bias is much smaller for larger
trials, because a large trial showing little or no effect is more likely to be published than a small trial with a similar
difference.
9. Computer software for sample size calculations
Most of the formulae given in this chapter are simple enough to do by hand, with the aid of a simple calculator.
However, computer software is also available to carry out some of these calculations. This can be particularly helpful
when a large number of calculations need to be carried out, for example, to explore sample size requirements for
different outcomes or under different assumptions, or to produce power curves. Most statistical packages have some
R = 1.
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provision for sample size calculations. Here we mention three packages which readers may find helpful when planning
field trials.
The sampsi command in Stata allows the user to obtain the required sample size for the comparison of means or
proportions. Alternatively, if the chosen sample sizes are entered, the user can determine the power that these will
provide. The command allows for different sample sizes in the two trial arms. The sample size formulae used by this
package differ slightly from those presented in this book, but the results should be quite similar in most cases.
The POWER and GLMPOWER procedures in the statistical analysis program package SAS can handle sample size
calculations for a range of situations, including survival analysis, as can the PASS module (a trial version of which is
available at <http://www.ncss.com>).
A variety of free sample size calculators may be found on the Internet. These include the program PS which is
described by Dupont and Plummer (1990) and available at
<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize>); and Open Epi which can be downloaded from
<http://www.openepi.com/Downloads/Downloads.htm>.
Table 5.6 gives a spreadsheet which facilitates the calculation of the required size (number of clusters) for a cluster
randomized trial, using the formulae given in Section 6 (as in Hayes and Moulton, 2009).
It is fairly straightforward to set up a spreadsheet, for example, in Excel, to apply any of the formulae given in this
chapter. The freeware computer package Epi-Info has a useful component, called StatCalc, for calculating sample sizes
for simple trials.
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Power curves for a trial of the effect of mosquito-nets on malaria deaths.
Malaria death rate in the control group assumed to be 10/1000/year. R, relative rate in the intervention group.
Assumes equal-sized groups, two-sided test, and significance p < 0.05.
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Figure 5.2
Number of communities required in each group in a trial of the effect of mosquito-nets against clinical malaria.
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Tables
Table 5.1 Relationship between  and % power (numbers in the body of the table show power
corresponding to each value of
First decimal place of 
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
−3.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−2.0 2.3 1.8 1.4 1.1 0.8 0.6 0.5 0.3 0.3 0.2
−1.0 15.9 13.6 11.5 9.7 8.1 6.7 5.5 4.5 3.6 2.9
−0.0 50.0 46.0 42.1 38.2 34.5 30.9 27.4 24.2 21.2 18.4
+0.0 50.0 54.0 57.9 61.8 65.5 69.1 72.6 75.8 78.8 81.6
+1.0 84.1 86.4 88.5 90.3 91.9 93.3 94.5 95.5 96.4 97.1
+2.0 97.7 98.2 98.6 98.9 99.2 99.4 99.5 99.7 99.7 99.8
+3.0 99.9 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0
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Table 5.2 Sample size requirements for comparison of proportions
Smaller prop. Difference 
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60
0.05 435 141 76 50 36 28 22 18 15 13 11 10
583 189 102 67 48 37 30 25 21 18 15 13
719 233 126 83 60 46 37 30 26 22 19 16
0.10 686 200 101 63 44 33 26 21 17 14 12 10
919 268 135 84 59 44 34 28 23 19 16 14
1134 330 166 104 72 54 42 34 28 24 20 17
0.15 906 251 122 74 50 37 28 22 18 15 13 10
1212 336 163 98 67 49 38 30 24 20 17 14
1497 415 201 122 83 60 46 37 30 25 21 18
0.20 1094 294 139 82 55 40 30 24 19 16 13 11
1464 394 186 110 74 53 40 31 25 21 17 15
1808 486 230 136 91 66 50 39 31 26 21 18
0.25 1250 329 153 89 59 42 31 24 19 16 13 11
1674 441 205 119 79 56 42 32 26 21 17 14
2067 544 253 147 97 69 52 40 32 26 21 18
0.30 1376 357 163 94 61 43 32 24 19 16 13 10
1842 478 219 126 82 58 43 33 26 21 17 14
2274 590 270 156 101 71 53 40 32 26 21 17
0.35 1470 376 170 97 63 44 32 24 19 15 12 10
1968 504 228 130 84 58 43 32 25 20 16 13
2430 622 282 160 103 72 53 40 31 25 20 16
0.40 1533 388 174 98 63 43 31 24 18 14 11
2052 520 233 131 84 58 42 31 24 19 15
2534 642 287 162 103 71 52 39 30 24 19
0.45 1564 392 174 97 61 42 30 22 17 13
2094 525 233 130 82 56 40 30 23 18
2586 648 287 160 101 69 50 37 28 22
0.50 1564 388 170 94 59 40 28 21 15
2094 520 228 126 79 53 38 28 21
2586 642 282 156 97 66 46 34 26
0.55 1533 376 163 89 55 37 26 18
2052 504 219 119 74 49 34 25
2534 622 270 147 91 60 42 30
0.60 1470 357 153 82 50 33 22
1968 478 205 110 67 44 30
2430 590 253 136 83 54 37
0.65 1376 329 139 73 44 28
1842 441 186 98 59 37
p1 D = −p2 p1
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Smaller prop. Difference 
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 0.55 0.60
2274 544 230 121 72 46
0.70 1250 294 122 63 36
1674 394 163 84 48
2067 486 201 104 60
0.75 1094 251 101 50
1464 336 135 67
1808 415 166 83









Shown in the body of the table are the sample sizes required in each group to give the specified power.
Upper figure: power, 80%; middle figure: power, 90%; lower figure: power, 95%. Using a two-sided significance test with  The
two groups are assumed to be of equal size.
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Table 5.3 Sample size requirements for comparison of rates
Relative rate R Expected events in group 2 to give
80% power 90% power 95% power
0.1 10.6 14.3 17.6
0.2 14.7 19.7 24.3
0.3 20.8 27.9 34.4
0.4 30.5 40.8 50.4
0.5 47.0 63.0 77.8
0.6 78.4 105.0 129.6
0.7 148.1 198.3 244.8
0.8 352.8 472.4 583.2
0.9 1489.6 1994.5 2462.4
1.1 1646.4 2204.5 2721.6
1.2 431.2 577.4 712.8
1.4 117.6 157.5 194.4
1.6 56.6 75.8 93.6
1.8 34.3 45.9 56.7
2.0 23.5 31.5 38.9
2.5 12.2 16.3 20.2
3.0 7.8 10.5 13.0
5.0 2.9 3.9 4.9
10.0 1.1 1.4 1.8
Numbers in the body of the table are expected number of events required in group 2 to give specified power if relative rate in group 1 is R.
R, ratio of incidence rate in group 1 to incidence rate in group 2.
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Table 5.4 Summary of formulae for calculating trial size requirements for comparison of two groups
of equal size
Type of outcome Formula Notation Section in text
A: Choosing trial size to achieve adequate precision
Proportions: n = number in each group
R = prop. in group 1/prop.  in group 2
Gives 95% CI from R/f to Rf
3.1
Rates: e  = expected events in  group 2
R = rate in group 1/rate in  group 2
Gives 95% CI from R/f to Rf
3.2
Means: n = number in each group
 in group i
D = mean in group 1 − mean in group 2
Gives 95% CI of 
3.3
B: Choosing trial size to achieve adequate power
Proportions: n = number in each group
p  = proportion. in group i
p = average of  and 
4.1
Rates: y = person-years in each  group
r  = rate in group i
4.2
Means: n = number in each group
 in group i
 mean in group i
4.3
 for significance at 
Power 80%, 90%, 95%
n
= {[(R + 1)(1.96/ f)loge
2
/ (R )] − 2}p2
e2









n = [ 2p (1 − p)]( + )z1 z2 2




y = [ ( + )]( + )z1 z2 2 r1 r2




= [ ( + )]( + )z1 z2 2 σ21 σ22
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Table 5.5 Trial size necessary to achieve approximately the same power in a trial with two groups,
one of which contains k times as many individuals as the other
k
1 n n 2n
2 0.75n 1.5n 2.25n
3 0.67n 2.0n 2.67n
4 0.62n 2.5n 3.12n
5 0.60n 3.0n 3.60n
10 0.55n 5.5n 6.05n
100 0.50n 50.0n 50.50n
n1 n2 n1
+ n2
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Table 5.6 Spreadsheet calculation of the number of clusters required in an unmatched cluster
randomized trial. Table 5.6 shows the calculations, for some example situations, for (a) comparison
of proportions and (b) comparison of rates. Formulae are given which allow the calculation of
required trial size for any (unmatched) cluster randomized trial in an Excel spreadsheet











A B C D E F G H I J K L
0.95 0.80 1.96 0.84 7.85 2.0% 50% 1.0% 500 0.25 8.08 9
0.95 0.80 1.96 0.84 7.85 3.0% 50% 1.5% 500 0.25 6.51 7
0.95 0.80 1.96 0.84 7.85 4.0% 50% 2.0% 500 0.25 5.73 6
0.95 0.90 1.96 1.28 10.51 2.0% 50% 1.0% 500 0.25 10.48 11
0.95 0.90 1.96 1.28 10.51 3.0% 50% 1.5% 500 0.25 8.38 9
0.95 0.90 1.96 1.28 10.51 4.0% 50% 2.0% 500 0.25 7.33 8
0.95 0.80 1.96 0.84 7.85 2.0% 50% 1.0% 250 0.25 12.71 13
0.95 0.80 1.96 0.84 7.85 3.0% 50% 1.5% 250 0.25 9.57 10
0.95 0.80 1.96 0.84 7.85 4.0% 50% 2.0% 250 0.25 8.01 9
0.95 0.90 1.96 1.28 10.51 2.0% 50% 1.0% 250 0.25 16.68 17
0.95 0.90 1.96 1.28 10.51 3.0% 50% 1.5% 250 0.25 12.48 13
0.95 0.90 1.96 1.28 10.51 4.0% 50% 2.0% 250 0.25 10.38 11











A B C D E F G H I J K L
0.95 0.8 1.96 0.84 7.85 0.050 50% 0.025 300 0.25 6.46 7
0.95 0.8 1.96 0.84 7.85 0.050 45% 0.028 300 0.25 7.99 9
0.95 0.8 1.96 0.84 7.85 0.050 40% 0.030 300 0.25 10.18 11
0.95 0.8 1.96 0.84 7.85 0.050 35% 0.033 300 0.25 13.44 14
0.95 0.8 1.96 0.84 7.85 0.050 30% 0.035 300 0.25 18.57 19
0.95 0.8 1.96 0.84 7.85 0.050 50% 0.025 300 0.20 5.58 6
0.95 0.8 1.96 0.84 7.85 0.050 45% 0.028 300 0.20 6.86 7
0.95 0.8 1.96 0.84 7.85 0.050 40% 0.030 300 0.20 8.68 9
0.95 0.8 1.96 0.84 7.85 0.050 35% 0.033 300 0.20 11.39 12
0.95 0.8 1.96 0.84 7.85 0.050 30% 0.035 300 0.20 15.65 16
Excel expressions:
C = NORMSINV(1− (0.5*(1 − A))); D = NORMSINV(B)
K = 1 + E*((F*(1 − F)/I) + (H*(1 − H)/I) + (J*J)*((F*F) + (H*H)))/((H − F)^2)

















Box 5.1 The power of the trial depends on:
The value of the true difference between the study groups, in other words, the true effect of the intervention.
The greater the effect, the higher the power to detect the effect as statistically significant for a trial of a given
size.
The trial size. The larger the trial size, the higher the power.
The probability level (p-value) at which a difference will be regarded as ‘statistically significant’.
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